Angiomax Approved For Use In Percutaneous Coronary Intervention
This article was originally published in The Pink Sheet Daily
Executive Summary
The indication includes “provisional” use with concomitant glycoprotein IIb/IIIa inhibitors. FDA had previously found the supplemental NDA, based on the REPLACE-2 study, “not approvable.” The Medicines Company appears not to have needed an additional study.
You may also be interested in...
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
Angiomax Gains Second Label Expansion For 2005
Supplement cleared Nov. 30 allows use of the anticoagulant bivalirudin in percutaneous coronary intervention patients at risk for heparin-induced thrombocytopenia or thrombosis syndrome.